Pub Date : 2017-01-01DOI: 10.4172/2167-0250.1000192
Murcia Jdu, Manrique Iav, Herrera Jms
Traumatic urethrocavernous fistula may develop as an acute or late complication after blunt penile trauma, however reports on corpus spongiosum-cavernosum fistula have rarely been described. We report the case of a 24- year-old man with a corpus cavernosum-spongiosum fistula secondary to an untreated penile fracture, and it surgical management with acellular matrix graft. Penile fractures are urologic emergencies that, if not handled opportunely, can lead to serious sequels, early surgical management should be the treatment of choice. The appearance of a post-traumatic cavernospongous fistula is a rare complication with almost non-existent literature reported. However, ignorance of this pathology can significantly compromise the patient's quality of life.
{"title":"Erectile Dysfunction Secondary to a Posttraumatic Corpus Cavernosum-Spongiosum Fistula Treated by a Cellular Matrix Interposition","authors":"Murcia Jdu, Manrique Iav, Herrera Jms","doi":"10.4172/2167-0250.1000192","DOIUrl":"https://doi.org/10.4172/2167-0250.1000192","url":null,"abstract":"Traumatic urethrocavernous fistula may develop as an acute or late complication after blunt penile trauma, however reports on corpus spongiosum-cavernosum fistula have rarely been described. We report the case of a 24- year-old man with a corpus cavernosum-spongiosum fistula secondary to an untreated penile fracture, and it surgical management with acellular matrix graft. Penile fractures are urologic emergencies that, if not handled opportunely, can lead to serious sequels, early surgical management should be the treatment of choice. The appearance of a post-traumatic cavernospongous fistula is a rare complication with almost non-existent literature reported. However, ignorance of this pathology can significantly compromise the patient's quality of life.","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"6 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70784379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2167-0250.1000194
Y. Yumura, J. Kasuga, T. Kawahara, Y. Miyoshi, Y. Hattori, J. Teranishi, D. Takamoto, T. Mochizuki, H. Uemura
Objective: This study aimed to evaluate the efficacy and toxicity of cisplatin, methotrexate, and bleomycin (CMB) chemotherapy in patients with advanced, recurrent, or metastatic penile squamous cell carcinoma (PSCC). Methods: The CMB regimen was administered to 12 patients with advanced (n=7), recurrent (n=4), or metastatic (n=1) PSCC. Patients received a total of 21 cycles of CMB between 2002 and 2009, and were retrospectively reviewed for treatment efficacy and toxicity of the drugs. The mean patient age was 61 (61.0 ± 8.7) years. Patients received 20.0 mg/m2 of cisplatin intravenously on days 2-6; 200.0 mg/m2 of methotrexate intravenously on days 1, 15 and 22; and 10.0 mg/m2 of bleomycin as a bolus on days 2-6. The CMB regimen consisted of 21-28 days of treatment per cycle. Survival after CMB therapy and frequency and magnitude of adverse effects were assessed. Results: Of the 7 patients with advanced disease who received the CMB regimen as neoadjuvant and/or adjuvant treatment, 5 survived, 1 died of local recurrence and lung metastasis, and 1 died of interstitial pneumonia. Three of the 5 patients with recurrent or metastatic disease died of PSCC. One patient died of interstitial pneumonia due to CMB. Only 1 patient with inguinal lymph node metastasis after penectomy who underwent adjuvant CMB regimen had survived. Eight patients who were disease free survived longer than those who still had the disease. No adverse hematological effects of Grade 3 or higher were observed. Conclusion: The CMB regimen might be effective for advanced PSCC, but not for recurrent or metastatic PSCC. Two patients died of interstitial pneumonitis due to chemotherapy. Hence, we believe that the CMB regimen should not be used as a first-line treatment option in patients with advanced-stage or metastatic PSCC.
{"title":"Cisplatin, Methotrexate and Bleomycin for Advanced Recurrent or Metastatic Penile Squamous Cell Carcinoma","authors":"Y. Yumura, J. Kasuga, T. Kawahara, Y. Miyoshi, Y. Hattori, J. Teranishi, D. Takamoto, T. Mochizuki, H. Uemura","doi":"10.4172/2167-0250.1000194","DOIUrl":"https://doi.org/10.4172/2167-0250.1000194","url":null,"abstract":"Objective: This study aimed to evaluate the efficacy and toxicity of cisplatin, methotrexate, and bleomycin (CMB) chemotherapy in patients with advanced, recurrent, or metastatic penile squamous cell carcinoma (PSCC). Methods: The CMB regimen was administered to 12 patients with advanced (n=7), recurrent (n=4), or metastatic (n=1) PSCC. Patients received a total of 21 cycles of CMB between 2002 and 2009, and were retrospectively reviewed for treatment efficacy and toxicity of the drugs. The mean patient age was 61 (61.0 ± 8.7) years. Patients received 20.0 mg/m2 of cisplatin intravenously on days 2-6; 200.0 mg/m2 of methotrexate intravenously on days 1, 15 and 22; and 10.0 mg/m2 of bleomycin as a bolus on days 2-6. The CMB regimen consisted of 21-28 days of treatment per cycle. Survival after CMB therapy and frequency and magnitude of adverse effects were assessed. Results: Of the 7 patients with advanced disease who received the CMB regimen as neoadjuvant and/or adjuvant treatment, 5 survived, 1 died of local recurrence and lung metastasis, and 1 died of interstitial pneumonia. Three of the 5 patients with recurrent or metastatic disease died of PSCC. One patient died of interstitial pneumonia due to CMB. Only 1 patient with inguinal lymph node metastasis after penectomy who underwent adjuvant CMB regimen had survived. Eight patients who were disease free survived longer than those who still had the disease. No adverse hematological effects of Grade 3 or higher were observed. Conclusion: The CMB regimen might be effective for advanced PSCC, but not for recurrent or metastatic PSCC. Two patients died of interstitial pneumonitis due to chemotherapy. Hence, we believe that the CMB regimen should not be used as a first-line treatment option in patients with advanced-stage or metastatic PSCC.","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"6 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70784435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2167-0250.1000184
M. Ivanović, N. Jeyadevan, R. Jeyendran
{"title":"Fertility of 25 year Cryostored Sperm of a Cancer Survivor","authors":"M. Ivanović, N. Jeyadevan, R. Jeyendran","doi":"10.4172/2167-0250.1000184","DOIUrl":"https://doi.org/10.4172/2167-0250.1000184","url":null,"abstract":"","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"6 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70783968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2167-0250.1000191
E. F. Branigan, A. Estes, K. Walker
Objective: To compare the effectiveness of IUI, based on Pre-treatment Semen analysis results, in treating male factor infertility.Design: A retrospective cohort design of 1,768 infertile couples undergoing 5,219 IUI cycles, who had pretreatment advanced semen analysis were evaluated. An advanced semen analysis consists of a basic semen analysis and processed total motile sperm counts through a density gradient sperm prep and recording 24 hours sperm survival of these sperm culture media in an incubator. Logistic regression analysis was used to assess the significance of prognostic factors in sperm parameters to predict the pregnancy rates with IUI.Results: No basic semen analysis parameter accurately predicted IUI success. Clinical pregnancy rate for first cycle of IUI was 15.6% when >10 × 106 processed total motile sperm was available and 13.7% in all cycles. This group contained 1264/1768 (71.5%) of couples in the study. The pregnancy rate in the first cycle was 18.2% if their 24 hour survival was >70% and 15.9% in all cycles and 1008/1264 (57%) of couples were in this group. No pregnancy was achieved for processed total motile sperm counts <5 × 106 (168/1768) or 9.5% of couples and 3.6% for those with 24 hour survivals <30% in first cycle and 2.0% for all cycles for 601/1768 (34%) of the couples. Strong positive correlations between processed total motile sperm counts and PR (r=0.83; p<0.001) and between 24 hours survival and PR (r=0.79; p<0.001) were seen by linear regression analysis. High correlations were also noted between processed total motile sperm counts (r=0.71; p<0.001) and 24 hours survivals (r=0.76; p<001) in the advanced semen analysis and those in the IUI samples.Conclusion: Both processed total motile sperm counts and 24 hour survival are useful predictors of whether a couple should be treated with levels below threshold levels have a very poor prognosis with IUIs.
{"title":"The Effect of Processed Total Motile Sperm Counts and Twenty Four Hour Sperm Survival on the Efficacy of Intrauterine Insemination in Male Infertility","authors":"E. F. Branigan, A. Estes, K. Walker","doi":"10.4172/2167-0250.1000191","DOIUrl":"https://doi.org/10.4172/2167-0250.1000191","url":null,"abstract":"Objective: To compare the effectiveness of IUI, based on Pre-treatment Semen analysis results, in treating male factor infertility.Design: A retrospective cohort design of 1,768 infertile couples undergoing 5,219 IUI cycles, who had pretreatment advanced semen analysis were evaluated. An advanced semen analysis consists of a basic semen analysis and processed total motile sperm counts through a density gradient sperm prep and recording 24 hours sperm survival of these sperm culture media in an incubator. Logistic regression analysis was used to assess the significance of prognostic factors in sperm parameters to predict the pregnancy rates with IUI.Results: No basic semen analysis parameter accurately predicted IUI success. Clinical pregnancy rate for first cycle of IUI was 15.6% when >10 × 106 processed total motile sperm was available and 13.7% in all cycles. This group contained 1264/1768 (71.5%) of couples in the study. The pregnancy rate in the first cycle was 18.2% if their 24 hour survival was >70% and 15.9% in all cycles and 1008/1264 (57%) of couples were in this group. No pregnancy was achieved for processed total motile sperm counts <5 × 106 (168/1768) or 9.5% of couples and 3.6% for those with 24 hour survivals <30% in first cycle and 2.0% for all cycles for 601/1768 (34%) of the couples. Strong positive correlations between processed total motile sperm counts and PR (r=0.83; p<0.001) and between 24 hours survival and PR (r=0.79; p<0.001) were seen by linear regression analysis. High correlations were also noted between processed total motile sperm counts (r=0.71; p<0.001) and 24 hours survivals (r=0.76; p<001) in the advanced semen analysis and those in the IUI samples.Conclusion: Both processed total motile sperm counts and 24 hour survival are useful predictors of whether a couple should be treated with levels below threshold levels have a very poor prognosis with IUIs.","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"6 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70784735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-17DOI: 10.1002/j.1939-4640.2001.tb03584.x
Michael D. Griswold
{"title":"Memorial","authors":"Michael D. Griswold","doi":"10.1002/j.1939-4640.2001.tb03584.x","DOIUrl":"https://doi.org/10.1002/j.1939-4640.2001.tb03584.x","url":null,"abstract":"","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"22 6","pages":"1080-1081"},"PeriodicalIF":0.0,"publicationDate":"2015-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.1939-4640.2001.tb03584.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134807713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-17DOI: 10.1002/j.1939-4640.2001.tb03581.x
{"title":"Key Word Index to Volume 22","authors":"","doi":"10.1002/j.1939-4640.2001.tb03581.x","DOIUrl":"https://doi.org/10.1002/j.1939-4640.2001.tb03581.x","url":null,"abstract":"","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"22 6","pages":"1075-1077"},"PeriodicalIF":0.0,"publicationDate":"2015-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.1939-4640.2001.tb03581.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134799082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-17DOI: 10.1002/j.1939-4640.2001.tb03580.x
{"title":"Author Index to Volume 22","authors":"","doi":"10.1002/j.1939-4640.2001.tb03580.x","DOIUrl":"https://doi.org/10.1002/j.1939-4640.2001.tb03580.x","url":null,"abstract":"","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"22 6","pages":"1070-1074"},"PeriodicalIF":0.0,"publicationDate":"2015-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.1939-4640.2001.tb03580.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134807712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-17DOI: 10.1002/j.1939-4640.2001.tb03585.x
{"title":"TRAINING PROGRAM IN MALE INFERTILITY, FEMALE INFERTILITY, AND SEXUAL FUNCTION","authors":"","doi":"10.1002/j.1939-4640.2001.tb03585.x","DOIUrl":"https://doi.org/10.1002/j.1939-4640.2001.tb03585.x","url":null,"abstract":"","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"22 6","pages":"1082"},"PeriodicalIF":0.0,"publicationDate":"2015-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.1939-4640.2001.tb03585.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134807702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-17DOI: 10.1002/j.1939-4640.2001.tb03582.x
{"title":"AMERICAN SOCIETY OF ANDROLOGY (ASA) NEWS","authors":"","doi":"10.1002/j.1939-4640.2001.tb03582.x","DOIUrl":"https://doi.org/10.1002/j.1939-4640.2001.tb03582.x","url":null,"abstract":"","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"22 6","pages":"1078"},"PeriodicalIF":0.0,"publicationDate":"2015-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.1939-4640.2001.tb03582.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134807710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-17DOI: 10.1002/j.1939-4640.2001.tb03583.x
{"title":"27th Annual Meeting of the American Society of Andrology","authors":"","doi":"10.1002/j.1939-4640.2001.tb03583.x","DOIUrl":"https://doi.org/10.1002/j.1939-4640.2001.tb03583.x","url":null,"abstract":"","PeriodicalId":15029,"journal":{"name":"Journal of andrology","volume":"22 6","pages":"1079"},"PeriodicalIF":0.0,"publicationDate":"2015-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/j.1939-4640.2001.tb03583.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134807711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：